Abstract
Hypoxia, which is a lowered physiological oxygen tension, is an important biological signal as well as a component of many diseases. In central nervous system, hypoxia is associated with brain injury following the ischemic stroke. Recent studies indicate that hypoxia may not only induce a direct neuronal damage, but it may also initiate inflammatory responses by activating microglia. Toxic inflammatory mediators produced by activated microglia under hypoxic conditions exacerbate the neuronal injury during cerebral ischemia. Pharmacological inhibition of hypoxic activation of microglia may prove to be neuroprotective against ischemic stroke.
Keywords: hypoxia, microglia, inflammation, apoptosis, neurodegeneration, neuronal injury, ischemia
Current Neuropharmacology
Title: Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Volume: 3 Issue: 2
Author(s): Jiyeon Ock, Hee-Jung Cho, Su Hyung Hong, In Kyeom Kim and Kyoungho Suk
Affiliation:
Keywords: hypoxia, microglia, inflammation, apoptosis, neurodegeneration, neuronal injury, ischemia
Abstract: Hypoxia, which is a lowered physiological oxygen tension, is an important biological signal as well as a component of many diseases. In central nervous system, hypoxia is associated with brain injury following the ischemic stroke. Recent studies indicate that hypoxia may not only induce a direct neuronal damage, but it may also initiate inflammatory responses by activating microglia. Toxic inflammatory mediators produced by activated microglia under hypoxic conditions exacerbate the neuronal injury during cerebral ischemia. Pharmacological inhibition of hypoxic activation of microglia may prove to be neuroprotective against ischemic stroke.
Export Options
About this article
Cite this article as:
Ock Jiyeon, Cho Hee-Jung, Hong Hyung Su, Kim Kyeom In and Suk Kyoungho, Hypoxia as an Initiator of Neuroinflammation: Microglial Connections, Current Neuropharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570159053586681
DOI https://dx.doi.org/10.2174/1570159053586681 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT Inhibitor Phlorizin
Current Neurovascular Research Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets Pediatric Chronic Daily Headache
Current Pediatric Reviews The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine
CNS & Neurological Disorders - Drug Targets Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
Current Pharmaceutical Biotechnology Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research